Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 11,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

NCT07512427
View directory record Official record
Conditions
MASH
Interventions
OPK-88006, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

NCT02431260
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
INCB054329 Monotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 30, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

NCT04986423
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 30, 2026, 10:43 PM EDT
Completed No phase listed Observational

Prostate Cancer Upgrading Reference Set

NCT02189486
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
35 Years to 99 Years · Male only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Recruiting Phase 1 Interventional

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

NCT06305910
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
Interventions
Treatment with CD200AR-L
Drug
Lead sponsor
OX2 Therapeutics
Industry
Eligibility
2 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

NCT05187624
View directory record Official record
Conditions
Glioblastoma
Interventions
RO7428731
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 30, 2026, 10:43 PM EDT
Completed No phase listed Observational Results available

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

NCT02135679
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Radiotherapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

NCT00748579
View directory record Official record
Conditions
Heart Failure
Interventions
CK-1827452
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 30, 2026, 10:43 PM EDT
Withdrawn Phase 1 Interventional

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

NCT05720624
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm
Interventions
Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection, Magnetic Resonance Spectroscopic Imaging, Questionnaire Administration
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of AV-001 in Healthy Subjects

NCT04737486
View directory record Official record
Conditions
Covid19-associated ARDS, Covid19, ARDS
Interventions
AV-001, Placebo
Drug · Other
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Clinical Interventions to Mitigate Neurodevelopmental Risk

NCT04233489
View directory record Official record
Conditions
Child Development, Mother-Infant Interaction, Diabetes Mellitus, Gestational
Interventions
Family Nurture Intervention (FNI)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
12 Hours to 3 Days
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 30, 2026, 10:43 PM EDT
Active, not recruiting Phase 1 Interventional

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

NCT03186118
View directory record Official record
Conditions
CD 19+ Acute Leukemia
Interventions
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT01470313
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
PD-0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Upland, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 30, 2026, 10:43 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

VascTrac Peripheral Arterial Disease (PAD) Study

NCT03048890
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
Physical activity levels
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Results available

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

NCT01805024
View directory record Official record
Conditions
Congenital Muscular Dystrophy
Interventions
Omigapil
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
5 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

NCT02411162
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

NCT05384262
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

NCT01130662
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
combination therapy using decitabine and midostaurin
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 30, 2026, 10:43 PM EDT
Active, not recruiting No phase listed Observational

Upper Airway Microbial Development During the First Year of Life

NCT01978288
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Minute to 1 Week
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 30, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

NCT01078961
View directory record Official record
Conditions
Melanoma
Interventions
bortezomib, sorafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 30, 2026, 10:43 PM EDT